AnaptysBio, Inc. (ANAB)
NASDAQ: ANAB · Real-Time Price · USD
23.39
-0.43 (-1.81%)
At close: Jun 18, 2025, 4:00 PM
23.50
+0.11 (0.47%)
After-hours: Jun 18, 2025, 5:26 PM EDT
AnaptysBio Revenue
AnaptysBio had revenue of $27.77M in the quarter ending March 31, 2025, with 286.84% growth. This brings the company's revenue in the last twelve months to $111.87M, up 387.20% year-over-year. In the year 2024, AnaptysBio had annual revenue of $91.28M with 432.03% growth.
Revenue (ttm)
$111.87M
Revenue Growth
+387.20%
P/S Ratio
6.13
Revenue / Employee
$822,588
Employees
136
Market Cap
687.21M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 91.28M | 74.12M | 432.03% |
Dec 31, 2023 | 17.16M | 6.87M | 66.78% |
Dec 31, 2022 | 10.29M | -52.89M | -83.72% |
Dec 31, 2021 | 63.18M | -11.83M | -15.77% |
Dec 31, 2020 | 75.00M | 67.00M | 837.50% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ANAB News
- 9 days ago - AnaptysBio: Rosnilimab's RA Data Sets The Stage For Blockbuster Potential - Seeking Alpha
- 13 days ago - AnaptysBio: Positive RA Data Bodes Well For Continued Rosnilimab Advancement - Seeking Alpha
- 15 days ago - AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point - Benzinga
- 16 days ago - Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA - GlobeNewsWire
- 23 days ago - Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025 - GlobeNewsWire
- 6 weeks ago - Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - Anaptys Announces Stock Repurchase Plan - GlobeNewsWire
- 4 months ago - Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewsWire